Analystreport

Spero Therapeutics (NASDAQ:SPRO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Spero Therapeutics, Inc.  (SPRO) 
Last spero therapeutics, inc. earnings: 3/16 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: investors.sperotherapeutics.com/overview